Moleculin Biotech, INC 8-K filings

Moleculin Biotech entered into a waiver and consent agreement with an investor, modifying warrant terms and agreeing to a cash payment in exchange for waiving restrictions on a Variable Rate Transaction.

Moleculin Biotech filed an amended 8-K to correct a hyperlink error in a previous filing related to a script from a virtual investor event.

Moleculin Biotech is progressing towards the launch of its MIRACLE pivotal study for relapsed/refractory AML, with the first patient expected to be treated this quarter and a key data readout anticipated by year-end.

Moleculin Biotech's CEO, Walter Klemp, discussed the progress of the Phase 3 MIRACLE trial for Annamycin in treating relapsed or refractory acute myeloid leukemia (AML) during a virtual investor segment.

Moleculin Biotech reports positive progress in its Annamycin clinical trials, including accelerated timelines for Phase 3 data readouts and strong Phase 2 results in AML.

Moleculin Biotech has released a new corporate presentation, which is now available on their website, as part of a Regulation FD disclosure.

Moleculin Biotech has released an updated corporate presentation, which is now available on their website.

Moleculin Biotech's Annamycin shows significant activity against drug-resistant acute myeloid leukemia (AML) in preclinical studies, with potential for improved patient outcomes.

Moleculin Biotech announced new findings indicating that Annamycin can overcome resistance to Venetoclax in acute myeloid leukemia (AML), with promising preclinical and clinical data.

Moleculin Biotech released a new corporate presentation on November 18, 2024, which is now available on the company's website.

Moleculin Biotech released an updated corporate presentation on its website on November 14, 2024.

Moleculin Biotech has amended its Phase 3 clinical trial protocol for Annamycin, allowing for an earlier unblinding of data and potentially accelerating the drug's approval timeline.

Moleculin Biotech has secured Institutional Review Board approval to begin its Phase 3 MIRACLE trial for Annamycin in combination with Cytarabine for the treatment of relapsed or refractory acute myeloid leukemia.

Moleculin Biotech has released an investor presentation, providing an update on the company's activities.

Moleculin Biotech reports third quarter 2024 financial results and provides a corporate update, highlighting progress in its Annamycin clinical trials and upcoming Phase 3 study.

Moleculin Biotech will release its financial results for the quarter ending September 30, 2024, on November 8, 2024, followed by a conference call on November 11, 2024.

Moleculin Biotech's stockholders approved the 2024 Stock Plan, elected directors, and ratified the appointment of Grant Thornton LLP as their independent auditor at the 2024 Annual Meeting.

Moleculin Biotech released the transcript of its Virtual Acute Myeloid Leukemia KOL event, emphasizing the potential of Annamycin as a non-cardiotoxic treatment option.

Moleculin Biotech will host a virtual event featuring key opinion leaders to discuss their ongoing Phase 3 clinical trial for Annamycin in treating relapsed or refractory Acute Myeloid Leukemia (AML).

Moleculin Biotech released a new corporate presentation on October 2, 2024, providing an update on the company's activities.

Moleculin Biotech reports positive in vivo efficacy data for Annamycin, showing significant tumor growth inhibition and survival extension in lung cancer models, with high drug concentration in the lungs and no cardiotoxicity.

Moleculin Biotech's CEO, Walter Klemp, discussed the company's Phase 2 clinical trial of a STAT3 inhibitor combined with radiation for glioblastoma treatment in a recent investor segment.

Moleculin Biotech, Inc. has released a new corporate presentation, which is now available on the company's website.

Moleculin Biotech has initiated a Phase 2 clinical trial evaluating WP1066 in combination with radiation therapy for the treatment of glioblastoma, with the first patients now enrolled and treated.

Moleculin Biotech has successfully closed a public offering, raising $5.5 million upfront with the potential for an additional $11 million upon full exercise of milestone-linked warrants.

Moleculin Biotech has priced a public offering expected to raise $5.5 million initially, with the potential for an additional $11 million upon full exercise of warrants.

Moleculin Biotech is moving forward with a pivotal Phase 3 clinical trial for Annamycin in combination with cytarabine for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) after a positive meeting with the FDA.

Moleculin Biotech is advancing Annamycin, in combination with Cytarabine, to a Phase 3 pivotal trial for the treatment of AML patients who are refractory to or relapsed after induction therapy.

Moleculin Biotech will host a webcast to discuss its plans to advance Annamycin in combination with Cytarabine to a Phase 3 pivotal trial for the treatment of AML patients.

Moleculin Biotech, Inc. has released a new corporate presentation, which is available on the company's website.